Search
20/01/2026
Cardiovascular biomarkers and preeclampsia: A narrative review
Ullmo, J, Nan, MN, Cruz-Lemini, M, Garrido-Gimenez, C, Platero, J, García-Osuna, A, García-Manau, P, Twickler, M, Llurba, E. Cardiovascular biomarkers and preeclampsia: A narrative review. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2026; 56(1)DOI:10.1111/eci.70123. PMID:41059676. IF:3.600(Q1/2D).
01/10/2024
PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia.
Borràs C, Canyelles M, Girona J, Ibarretxe D, Santos D, Revilla G, Llorente-Cortes V, Rotllan N, Kovanen PT, Jauhiainen M, Lee-Rueckert M, Masana L, Arrieta F, Martínez-Botas J, Gómez-Coronado D, Ribalta J, Tondo M, Blanco-Vaca F, Escolà-Gil JC. PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia.. Jacc-Basic To Translational Science. 2024; 9(10)DOI:10.1016/j.jacbts.2024.06.008. PMID:39534644. IF:(Q/D).
01/08/2024
Exploring Plasma Coenzyme Q10 Status in Paediatric Dyslipidaemia
Minguez, B, de Los Santos, M, Garcia-Volpe, C, Molera, C, Paredes-Fuentes, AJ, Oliva, C, Arias, A, Rodriguez-Gonzalez, H, Yubero, D, Tondo, M, Santos-Ocaña, C, Meavilla, S, Artuch, R. Exploring Plasma Coenzyme Q10 Status in Paediatric Dyslipidaemia. Antioxidants. 2024; 13(8)DOI:10.3390/antiox13080966. PMID:39199213. IF:6.600(Q1/1D).
01/05/2026
Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory study
Garcia-Pagan, JC, Gluud, LL, Mandorfer, M, Schattenberg, JM, De Gottardi, A, Berzigotti, A, Fortea, JI, Martínez, AA, Alvarado-Tapias, E, Berning, M, Petryszyn, P, Henricson, E, Berglind, N, Lin, M, Persson, K, Mercier, A, Ambery, P, Bosch, J, Oscarsson, J, Rockey, DC. Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory study. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2026; 92(5)DOI:10.1002/bcp.70332. PMID:41362018. IF:3.000(Q2/4D).